La sclérose systémique est une maladie autoimmune dont l’une des complications majeures est la fibrose. La DNA topoisomérase I (topo) est l’un des principaux autoantigènes associés à cette maladie. Toutefois, aucun lien n’a encore pu être établi entre la présence des anti-topo et le développement de la fibrose. Les travaux antérieurs du laboratoire d’accueil ont montré une interaction directe de la topo avec la surface des fibroblastes et la matrice extracellulaire. Nous avons voulu caractériser ces interactions du point de vue moléculaire. La topo a donc été exprimée sous forme de 5 fragments, déterminés à partir de ses principaux domaines structuraux et de ses épitopes majeurs, chez E. coli. Les fragments purifiés ont été analysés pour leur interaction avec l’héparine, représentant les héparane sulfates de la surface des fibroblastes, et avec des protéines purifiées de la matrice extracellulaire. Nous avons montré que le fragment topo-N est le principal responsable de l’interaction avec l’héparine, ce qui suggère donc l’implication potentielle de ce domaine dans l’interaction de la topo avec la surface des fibroblastes. Le fragment topo-DIDII est responsable de l’interaction avec la plupart des protéines de la matrice extracellulaire étudiées, alors que le fragment topo-H15 n’interagit qu’avec la vitronectine. Aucune interaction des fragments topo-DIII et topo-C n’a été décelée. Ces résultats pourront maintenant servir à mieux comprendre le rôle potentiel de la topo et des autoanticorps circulants anti-topo dans la fibrose présente chez les personnes atteintes de sclérose systémique en contribuant à l’identification de la cible de la topo sur les fibroblastes. / Systemic sclerosis is an autoimmune disease in which one of the major complications is fibrosis. DNA topoisomerase I (topo) is a major autoantigen associated with this disease. However, no link has yet been established between the presence of anti-topo and the development of fibrosis. Previous work of the host laboratory showed a direct interaction of the topo with the surface of fibroblasts and extracellular matrix. We wanted to characterize these interactions at the molecular level. Topo was expressed in 5 fragments, determined from its main structural domains and its major epitopes, in E. coli. The purified fragments were analyzed for their interaction with heparin, representing heparan sulfates on the surface of fibroblasts, and with purified proteins of the extracellular matrix. We have shown that the topo-N fragment is responsible for interaction with heparin, suggesting hence, potential involvement of this domain in the interaction of topo with the surface of fibroblasts. The topo-DIDII fragment is responsible for the interaction with most proteins of the extracellular matrix studied, whereas the topo-H15 fragment only binds to vitronectin. No interaction of fragments topo-DIII and topo-C was found. These results can now be used to better understand the potential role of topo and circulating anti-topo autoantibodies in the fibrosis present in patients with systemic sclerosis in helping to identify the target of topo on fibroblasts.

La sclérose systémique (ScS) est une maladie auto-immune dévastatrice d'étiologie inconnue. Le dysfonctionnement immunitaire, la fibrose et la vasculopathie sont les trois principales caractéristiques de cette maladie. Une récente étude a révélé un nouveau lien entre l'auto-immunité et la fibrose, par la présence d'auto-anticorps stimulant le récepteur du facteur de croissance dérivé des plaquettes (PDGFR) des fibroblastes. Ces auto-anticorps sont capables de stimuler les espèces réactives de l'oxygène et d’activer la kinase régulée par un signal extracellulaire (ERK1/2). L’hypothèse que nous formulons est que les cellules musculaires lisses vasculaires (VSMCs) exprimant conjointement les PDGFR, répondront elles aussi aux autoanticorps anti-PDGF-R. Le travail présenté ici vise à valider la présence d'auto-anticorps PDGFR dans les sérums de patients ScS, et à caractériser ensuite la réponse de VSMCs exposées à de l'immunoglobuline G (IgG) de ces sérums, en mesurant l’activation des cascades de signalisation spécifiques, ainsi que l'induction des gènes impliqués dans la réponse fibrotique. Nos résultats démontrent la présence d'une fraction IgG stimulant une réponse phénotypique dans les cultures de VSMCs. Notamment, d’importantes régulations positive et négative des gènes pro-fibrotiques tgfb1 et tgfb2 respectivement, ont été observées dans les VSMCs exposées à des fractions de ScS-IgG. Les fractions de IgG positives pour l'activation de ERK étaient présentes dans la plupart, mais pas dans tous les échantillons de SSc (68%, 19/28), et moins présentes dans les contrôles 27% (11/3). Bien que, les fractions de SSc-IgG ont pu considérablement immunoprécipiter le PDGFR, l'utilisation d'un inhibiteur spécifique des récepteurs au PDGF (AG1296), n'a pas inhibé l'activation de ERK médiée par les fractions de SSc-IgG. Globalement, nos résultats indiquent la présence d'autoanticorps stimulants avec activité pro-fibrotique dans les sérums des patients ScS. Des travaux sont en cours pour identifier l'entité moléculaire responsable de la réponse d’IgG observée dans les cultures de VSMCs. / Systemic Sclerosis (SSc) is a devastating autoimmune disease of unknown etiology. Immune dysfunction, fibrosis and vasculopathy are the three major features of the disease; however, the interactions between these components are poorly understood. A novel link between autoimmunity and fibrosis has been proposed by the presence of stimulatory autoantibodies to the platelet-derived growth factor receptor (PDGFR) on fibroblasts. These autoantibodies were capable of stimulating reactive oxygen species and subsequent activation of ERK1/2. If the anti-PDGFR autoantibodies are present in the systemic circulation of SSc patients, they will most certainly encounter vascular smooth muscle cells (VSMCs). The latter are known to express the PDGFR and response to PDGF, which is a known phenotypic modulator of VSMCs. The work presented here seeks to readdress the presence of stimulatory anti-PDGFR autoantibodies in serum derived from SSc-patients and to characterize the effects of SSc-IgG on VSMCs by measuring the activation of specific signaling cascades and the induction of genes involved in fibrotic responses. Our results demonstrate the presence of an IgG fraction stimulating a phenotypic response in cultured VSMCs. Notably, a significant up-regulation of the pro-fibrotic gene tgfb1 and a significant down-regulation of the anti-fibrotic gene tgfb2 were observed in VSMC exposed to SSc-IgG fractions. Positive IgG fractions for ERK activation were present in most, but not all, SSc samples (68%, 19/28), and they were less present in controls (27%) (3/11). Although, the SSc-IgG fractions were able to significantly immunoprecipitate the PDGFR, the use of a selective PDGFR inhibitor, AG1296, did not inhibit the activation of ERK mediated by SSc-IgG fractions. Altogether, our findings suggest the presence of stimulatory autoantibodies with profibrotic activity in serum derived form SSc patients. Work is in progress to identify the molecular entity responsible for the IgG response observed in cultured VSMCs.

Le dysfonctionnement endothélial et le dérèglement du système immunitaire sont les deux principaux mécanismes physiopathologiques responsables de la fibrose de la peau et des organes internes dans la sclérodermie systémique (ScS). La pneumopathie interstitielle diffuse (PID) est devenue la principale cause de mortalité de la maladie. L'inflammation pulmonaire est la conséquence de l'activation du système immunitaire, qui stimule la NO synthase inductible (NOS-2) et augmente la production alvéolaire de monoxyde d'azote (NO). L'augmentation de la concentration alvéolaire de NO (CANO) est significativement corrélée à la sévérité de la PID chez les patients atteints de ScS. L'augmentation de la CANO est liée à l'effet inducteur du sérum des malades sur la prolifération des fibroblastes pulmonaires et leur différentiation en myofibroblastes, faisant ainsi le lien biologique entre l'inflammation alvéolaire et la fibrose pulmonaire dans la ScS. Nous avons ensuite testé la valeur prédictive de la CANO dans la détérioration de la PID. Les patients ayant une CANO supérieure à 5,3 ppb présentent un risque élevé (> 6 fois) de voir survenir l'aggravation de la fibrose pulmonaire ou le décès (évènement combiné) par rapport à ceux qui ont une CANO inférieure ou égale à 5,3 ppb. Une valeur de CANO supérieure ou égale à 8,5 ppb permet de détecter les patients avec un risque de 90% de survenue d'évènement combiné dans les trois ans. Ces patients pourraient alors bénéficier d'un traitement approprié précoce. Nous avons évalué l'inflammation pulmonaire dans deux modèles murins de fibrose pulmonaire induite par l'acide hypochloreux et la bléomycine, par la mesure non-invasive du NO expiré (FENO). Le pic d'augmentation de FENO se situe 4 semaines après le début des injections, et précède la fibrose pulmonaire, qui ne devient significative qu'à partir de 6 semaines d'intoxication. L'augmentation de la FENO est liée à l'augmentation de l'expression de la NOS-2 aussi bien aux niveaux des bronches qu'aux niveaux des alvéoles. Enfin, la forte production de NO constatée provoque un effet délétère direct sur le tissu pulmonaire attesté par la présence de 3-nitrotyrosines, marqueurs du stress nitrosatif.Mots-clés: sclérodermie systémique, pneumopathie interstitielle diffuse, monoxyde d'azote, physiopathologie. / Summary not transmitted

La nature du lien qui unit les deux aspects du système immunitaire, que sont la défense de l’hôte contre les agressions extérieures et la genèse des maladies auto- immunes, n’a pas été élucidée. L’axe IL-23/Th17 joue un rôle dans les deux versants, ce qui le place en bonne position pour être un potentiel chaînon manquant. Objectif : connaître l’implication de cet axe dans un modèle infectieux, Mycoplasma hominis, et un modèle de maladie auto-immune, la sclérodermie systémique (ScS), dans lesquels il n’a pas encore été étudié. Les lipoprotéines membranaires de M. hominis sont capables d’induire une maturation des cellules dendritiques humaines. Elle s’accompagne d’une sécrétion d’IL-23 variable selon l’origine clinique des isolats, via TLR2, et d’une polarisation vers la voie Th17. Nous avons observé une augmentation de la fréquence des cellules Th17 et Th22 dans le sang périphérique des patients ScS, potentialisée par l’iloprost, via entre autres la production monocytaire d’IL-23. Dans la peau des patients ScS, il existe une augmentation des cellules produisant l’IL-17 inversement corrélé au score de fibrose cutanée. In vitro, l’IL-17 est capable d’inhiber partiellement l’expression d’α-SMA induite par le TGF-ß et d’induire la sécrétion de MMP1 par des fibroblastes dermiques humains. L’axe IL-23/IL-17 et les cellules Th17 jouent un rôle dans la défense contre M. hominis et dans la physiopathologie de la ScS. / Relationship between both aspects of the immune system, ie host defense against external aggression and genesis of autoimmune diseases, has not been elucidated. IL-23/Th17 axis plays a role in both sides, which puts him in a good position to be a potential missing link. Objective: To understand the implication of this axis in a model of infection, Mycoplasma hominis, and a model of autoimmune disease, systemic sclerosis (SSc), in which it has not yet been studied.
The membrane lipoproteins of M. hominis are capable of inducing human dendritic cell maturation. It occurs along with an IL-23 secretion changing with the clinical origin of isolates, via TLR2, and a T cell polarization towards Th17. Then we observed an increase in the Th17 and Th22 cell frequency in peripheral blood of SSc patients, further enhanced by iloprost via monocyte production of IL-23 among others. In the skin of SSc patients, we showed an increase in IL-17-producing cells with an inverse correlation to the skin fibrosis score. In vitro, IL-17 is able to partially inhibit the expression of α-SMA induced by TGF-ß and to induce the secretion of MMP1 in human dermal fibroblasts. The IL-23/IL-17 axis and Th17 cells play a role in defense against M. hominis and in the pathogenesis of SSc.

O objetivo deste estudo foi avaliar as medidas de volume e densidade pulmonar em exames de tomografia computadorizada de alta resolução (TCAR) de tórax de pacientes com esclerose sistêmica (ES), antes e após o transplante de medula óssea (TMO). As medidas foram comparadas com a avaliação funcional e resposta ao tratamento. Este foi um estudo retrospectivo observacional. A avaliação clínica e tomográfica foi realizada antes, após 6 e 18 meses do TMO, dos pacientes com ES que realizaram o procedimento entre 2011 e 2017. A análise quantitativa da TCAR foi feita utilizando programa totalmente automatizado (Yacta), capaz de obter o volume pulmonar, a densidade pulmonar média e os percentis de atenuação (P10, P40, P50, P80 e P90). Os dados clínicos, incluindo o resultado das espirometrias, foram obtidos dos prontuários eletrônicos dos pacientes. A capacidade vital forçada (CVF) aos 18 meses foi utilizada para classificar os pacientes em grupo \"melhor resposta\" (aumento >= 10% dos valores da CVF) ou \"resposta estável\" (redução, estabilidade ou aumento < 10% na CVF). Nenhum paciente apresentou redução da CVF > 10% pós-TMO. Foram incluídos 33 pacientes, com alteração tomográfica ou da função pulmonar antes da realização do TMO. O grupo \"melhor resposta\" foi composto por 15 pacientes (45,4%, 4 homens, idade média de 32,1 anos), enquanto o grupo \"resposta estável\" por 18 pacientes (54,6%, 4 homens, idade média de 37,5 anos). A análise quantitativa das TCAR não demonstrou diferença significativa entre os grupos na fase pré-TMO. No grupo \"melhor resposta\" houve redução significativa da densidade pulmonar média e dos valores dos percentis de densidade após o TMO, destacando-se os percentis 80 e 90. No grupo \"resposta estável\" não houve alteração significativa pós-TMO nos valores de volumes e densidades pulmonares. Concluímos que a análise quantitativa automática da TCAR de pacientes com ES foi capaz de identificar redução significativa da densidadepulmonar nos pacientes com melhora significativa da função pulmonar. Inferimos que, além dos volumes e densidades médias, podem ser utilizados também os percentis de densidade como parâmetro no acompanhamento da doença intersticial. Esta ferramenta pode representar um biomarcador na avaliação de tratamento da doença intersticial pulmonar na ES, complementando as provas de função pulmonar. / The purpose of this study was to evaluate pulmonary volume and density measurements in high resolution computed tomography (HRCT) scans of patients with systemic sclerosis (SSc) before and after bone marrow transplantation (BMT). Measurements were compared with functional assessment and response to treatment. This was a retrospective observational study. Clinical and tomographic evaluation of patients was performed before, after 6 and 18 months of BMT, for patients submitted to the procedure between 2011 and 2017. The quantitative analysis of HRCT scans was performed using a fully automated program (Yacta), capable of obtaining lung volume, density and attenuation percentiles (P10, P40, P50, P80 and P90). Clinical data, including the results of spirometry, were obtained from patients\' electronic records. Forced vital capacity (FVC) at 18 months was used to classify patients into \"best response\" group (>= 10% increase in FVC values) or \"stable response\" (reduction, stability or FVC increase < 10%). No patient had FVC reduction > 10% after BMT. Thirty-three patients were included, with tomographic or pulmonary function alterations before the BMT. The \"best response\" group consisted of 15 patients (45.4%, 4 men, mean age 32.1 years), while the \"stable response\" group comprised 18 patients (54.6%, 4 men, mean age of 37.5 years). Quantitative analysis of HRCT did not show a significant difference between the groups in the pre-BMT evaluation. In the \"best response\" group there was a significant reduction in mean lung density and density percentile values after BMT, with emphasis on the 80th and 90th percentiles. In the \"stable response\" group there was no significant post-BMT change in lung volumes and pulmonary densities. We conclude that the quantitative automatic HRCT analysis of patients with ES identified a significant reduction in pulmonary density in patients with improved pulmonary function. We speculate that, in addition to the mean volumes and densities, density percentiles may also be used as a parameter in the follow-up ofpatients with interstitial lung disease. This tool may represent a biomarker in the evaluation of interstitial lung disease treatment in patients with SSc, complementing pulmonary function tests.

Objetivo: Verificar o remodelamento da pele e produção de anticorpos em modelo experimental de esclerodermia em coelhos, após indução de tolerância nasal com colágeno tipo V. Métodos: Coelhas Nova Zelândia (N=12) foram imunizadas com 1mg/ml de colágeno V (Col V) em adjuvante completo de Freund e dois reforços com adjuvante incompleto de Freund. Seis coelhas imunizadas receberam uma dose diária de 25ug de Col V, iniciado via nasal (grupo tolerado) 150 dias do começo das imunizações e seis animais foram somente imunizadas (grupo imunizado). Um grupo imunizado com adjuvante de Freund serviu como controle. Biopsias de pele foram coletadas em 0, 75, 120, 150 e 210 dias e coradas pelo H&E, tricrômico de Masson e Sírius red para analise morfológica e morfométrica. Os colágenos I, III e V, além de TGFbeta e PDGF foram imunomarcados por imunofluorescência. Os soros dos animais foram coletados em 0, 150 e 210 dias para determinar anticorpos anti-colágenos I, III, IV e V e anti-nucleares. Resultados: Os animais imunizados mostraram progressivo decréscimo da derme papilar, atrofia de anexos, aumento no depósito dos colágenos I, III e V e aumento da expressão de TGFbeta e PDGF. Os tolerados apresentaram aumento dos anexos cutâneos e significante diminuição no depósito dos colágenos I, III e V, TGFbeta e PDGF. O grupo de imunizados e de tolerados apresentaram anticorpos anti-colágenos III e IV e antinucleares. Conclusões: A indução de tolerância nasal com Col V diminuiu o remodelamento da pele observado no modelo experimental de esclerodermia e inibiu a síntese de citocinas fibrogênicas. Portanto, a tolerância nasal com Col V pode ser uma opção terapêutica promissora para o controle do remodelamento cutâneo em pacientes com esclerodermia. / Objective: Our aim was to verify the skin remodeling and antibody production in experimental model of scleroderma in rabbits, after induction of tolerance by daily nasal administration of human type V collagen (Col V). Methods: Female New Zealand rabbits (N=12) were immunized with 1mg/ml of Col V in complete Freund\'s adjuvant, followed by more two boosters in incomplete Freund\'s adjuvant. Six immunized rabbits received daily nasal administrating of 25ug of Col V (tolerated group), started 150 days after the first immunization, and the others animals (N=6) were only immunized (immunized group). Finally a group of rabbits immunized with Freund\'s adjuvant served as control. Skin biopsies were collected at 0, 75, 120, 150 and 210 days, and stained with H&E, Masson\'s trichrome and Sirius red for morphological and morphometric analysis. Types I, III and V collagen, TGFbeta and PDGF were immunostained by immunofluorescence. The sera of animals were colleted at 0, 150 and 210 days to determine anti types I, III, IV and V collagen and antinuclear antibodies. Results: The immunized animals showed progressive decrease of papillary dermis, appendages atrophy, increase of types I, III and V collagen deposition and increased expression of TGF-beta and PDGF. The tolerated rabbits presented increase of cutaneous appendages and significant decrease of types I, III and V and TGF-beta and PDGF. Both immunized and tolerated rabbits presented anti types III and IV antibodies and antinuclear antibodies. Conclusions: Col V nasal tolerance reduced skin remodeling in experimental model of scleroderma and inhibited synthesis of fibrotic cytokines. Therefore, the nasal tolerance with type V collagen can be a promising therapeutic option to control the skin remodeling in patients with scleroderma.

Esclerose sistêmica (ES) é uma doença autoimune caracterizada por fibrose cutânea associada a envolvimento visceral, levando a diminuição da capacidade física, limitação no desempenho das atividades de vida diária e prejuízo na qualidade de vida. O transplante autólogo de células-tronco hematopoéticas (TACTH) vem sendo estudado como uma alternativa terapêutica para pacientes com ES, proporcionando melhora do acometimento cutâneo e ao menos estabilização do quadro pulmonar. O objetivo deste estudo é avaliar o impacto do TACTH no acometimento da pele, capacidade funcional e qualidade de vida em pacientes com ES. Trata-se de um estudo longitudinal e prospectivo, conduzido no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. Os pacientes com ES submetidos ao TACTH foram avaliados inicialmente, e reavaliados 6 e 12 meses após o tratamento. A avaliação consistiu dos seguintes itens: acometimento da pele, avaliado pelo escore modificado de Rodnan (mRSS), função pulmonar (capacidade vital forçada, CVF e capacidade de difusão do monóxido de carbono, DLCO), força muscular respiratória (pressão inspiratória máxima - PImáx, e pressão expiratória máxima - PEmáx), mobilidade tóraco-abdominal pela cirtometria, avaliação funcional dos membros superiores (força de preensão das mãos, amplitude de movimento pela goniometria, distância finger-to-palm - FTP, questionários Disabilities of the arm, shoulder and hands - DASH, e Cochin hand functional scale - CHFS), abertura oral, teste de caminhada de seis minutos (TC6) e questionário de qualidade de vida Medical Outcomes Study - 36 item short-form (SF-36). Vinte e sete pacientes com ES foram avaliados antes e 6 meses após o transplante, e 22 desses pacientes foram adicionalmente avaliados aos 12 meses pós-transplante. Quando comparadas com os valores iniciais, pré-transplante, observou-se melhora significativa das variáveis mRSS, PImáx, PEmáx, cirtometria, força de preensão das mãos dominante e não-dominante, amplitudes de movimento articulares, FTP das mãos dominante e não-dominante, DASH, CHFS, abertura oral, distância percorrida no TC6, domínios capacidade funcional, aspectos físicos, dor, estado geral de saúde, vitalidade, aspectos sociais e saúde mental do SF-36 e medidas sumárias de componentes físico e mental do SF-36, após o transplante. Houve estabilização da função pulmonar após o transplante. Houve correlação significativa entre o mRSS e medidas de amplitude de movimento de punho, entre a capacidade física avaliada pelo TC6 e o componente físico do SF-36 e entre o questionário DASH e o componente físico do SF-36. Em conclusão, o TACTH promove melhora significativa do acometimento da pele, da capacidade funcional e da qualidade de vida de pacientes com ES, até pelo menos 1 ano de seguimento após o transplante. Embora a função pulmonar tenha apenas se estabilizado, os pacientes apresentaram significativa melhora da capacidade física. / Systemic sclerosis (SSc) is an autoimune disease characterized by skin fibrosis, associated with internal organ involvement, leading to decreased physical capacity, limitations in daily life activities and impairment of quality of life. Autologous hematopoietic stem cell transplantation (AHSCT) has been studied as an alternative treatment for patients with severe SSc, and promotes improvement of skin involvement and, at least, pulmonary function stabilization. The aim of this study is to evaluate the impact of AHSCT in skin involvement, functional capacity and quality of life in SSc patients. This is a prospective and longitudinal study, conducted at the Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, University of São Paulo. SSc patients were evaluated before, and 6 and 12 months after transplant for skin involvement by modified Rodnan skin score (mRSS), pulmonary function (forced vital capacity, FVC, carbon monoxide diffusion capacity, DLCO), respiratory muscle strength (maximal inspiratory pressure - MIP, and maximal expiratory pressure - MEP), thoracoabdominal mobility by cirtometry, functional evaluation of upper limbs (hand grip strength, range of motion by goniometry, finger-to-palm distance - FTP, Disabilities of the arm, shoulder and hands questionnaire - DASH, and Cochin hand functional scale questionnaire - CHFS), mouth opening, six-minute walk test (6MWT) and quality of life by the Medical Outcomes Study - 36 item short-form (SF-36). Twenty-seven patients were evaluated before and at 6 months after transplant, 22 of which were additionally evaluated at 12 months after transplant. When compared to pre-transplant evaluations, patients presented significant improvement of mRSS, MIP, MEP, cirtometry, hand grip strength, range of motion measurement, FTP distance, DASH, COCHIN, mouth opening, distance in 6MWT, physical functioning, role-physical, bodily pain, general health, vitality, social functioning and mental health domains of SF-36, and summary measures of the SF-36 Physical Component score and Mental Component score after AHSCT. The pulmonary function stabilized after transplant. Significant correlations were observed between skin involvement and range of motion measures, physical capacity and quality of life, and DASH and quality of life. In conclusion, AHSCT significantly improves the functional status of SSc patients in the first year of follow-up. Although the pulmonary function remained stable after AHSCT, there was significant increase in the physical capacity of patients.

Recentemente, descobrimos que coelhos, Nova Zelândia, imunizados com colágeno tipo V humano mais adjuvante de Freund apresentavam fibrose e vasculite de órgãos normalmente afetados na esclerose sistêmica. Deste modo, nós estudamos o processo de fibrilogênese para identificar possíveis fatores envolvidos na alteração do remodelamento observado neste modelo de esclerodermia. Adicionalmente, fizemos uma comparação preliminar com pele humana obtida de pacientes com esclerodermia (n=3). Coelhos fêmeas, Nova Zelândia (n=14), foram imunizados subcutaneamente com duas doses de 1mg de colágeno V mais adjuvante completo de Freund, com intervalo de 30 dias, seguido de duas imunizações em adjuvante incompleto de Freund, via intramuscular, com intervalo de 15 dias. Os animais do grupo controle (n- 14) foram inoculados somente com adjuvante completo e incompleto de Freund, nas mesmas condições dos imunizados. Foram realizadas análises histológicas das peles dos animais e pacientes através da coloração com tricrômico de Masson e imunofluorescêcia, a fim de detectar fibras de colágeno e interação dos colágenos I, III e V. A análise da pele dos animais demonstrou depósito precoce de fibras de colágeno na derme após 7 dias da sensibilização, com aumento destes depósitos após 75 e 120 dias respectivamente. Depósito de colágeno na pele e atrofia de anexos foram mais intensos nos animais sacrificados em 120 dias e se correlacionaram com a quantidade aumentada de colágeno. Surpreendentemente, o colágeno V foi expresso em animais e pacientes, formando fibras densas e atípicas na derme. Sugerimos que esta expressão anômala de colágeno V, morfologicamente diferente, possa justificar o remodelamento observado na placa esclerodérmica / Recently, we discovered that New Zealand rabbits immunized with human type V collagen plus Freund`s adjuvant presented fibrosis and vasculitis of organs usually affected in systemic sclerosis. In this way, we studied the fibrillogenesis process regarding to identify any possible factor involved in altered remodeling observed in this scleroderma-like model. Additionally, we done a very preliminary comparison with human skins obtained from scleroderma patients (N=3). Female New Zealand rabbits (N=14) were immunized subcutaneously with two doses of 1mg collagen V plus complete Freunds adjuvant at a 30 days interval, followed by two additional intramuscular booster immunizations in incomplete Freunds adjuvant at a 15-day interval. Animals from control group (N=14), were only inoculated with complete and incomplete Freunds adjuvant given at same conditions of collagen type V group. Histological analysis of skins from animals and patients were done by Massons trichrome staining, and immunofluorescence method used to detect collagen fibers and interactions of types I, III and V collagen in the remodeling process. The analysis of animal skins showed precocious collagen fibril deposits in the dermis after 7 days of immunization and increase of this process in 75 and 120 days. Skin collagen deposit and atrophy of annexes were progressively more intense in late sacrificed animals and correlated with increased amount of collagen deposition. Surprisingly, type V collagen was over expressed both in animals and patients, forming dense and atypical collagen fibers in the dermis. We suggest that this anomalous expression of morphologically different type V collagen could justify the remodeling observed in scleroderma plaque

Introdução: A imunização de coelhos saudáveis com colágeno do tipo V (COLV) reproduz as principais manifestações da esclerose sistêmica (ES), incluindo fibrose, vasculopatia e produção de autoanticorpos específicos da doença. Estudos preliminares mostraram que, tanto na derme de animais imunizados com COLV (COLV-IM), como na derme de pacientes com ES, observa-se deposição aumentada de COLV anômalo, mas não se sabe qual a relevância clínica deste achado. O remodelamento da matriz extracelular é precoce nos animais COLV-IM, ocorrendo já no sétimo dia após a imunização, o que sugere que o COLV esteja relacionado com a injúria endotelial, evento primário envolvido na patogênese da ES. Desta forma, os objetivos do presente estudo foram avaliar a expressão de COLV na derme de controles saudáveis e de pacientes com ES e sua correlação com espessamento cutâneo, atividade e duração da doença; assim como pesquisar uma possível associação entre a deposição deste colágeno na derme com a expressão de marcadores de apoptose e de ativação endotelial em pacientes e no modelo animal induzido pela imunização com COLV. Pacientes e Métodos: Biópsias de pele de pacientes com ES (N=18, 6 com doença precoce e 12 com doença tardia) e de controles (N=10) pareados por idade e sexo, assim como biópsias de pele de coelhos imunizados com COLV + adjuvante de Freund (COV-IM, N=6) ou adjuvante de Freund (N=6) foram avaliadas. Nos pacientes com ES, o espessamento cutâneo foi avaliado por meio do escore de Rodnan Modificado (MRSS) e a atividade da doença foi calculada pelo índice de atividade de Valentini. Para realizar a quantificação por histomorfometria, o COLV na derme foi identificado por imunofluorescência. Caspase-3, endotelina-1, CTGF, TGF e VEGF nas células endoteliais dérmicas foram marcados por imunohistoquímica. Nos pacientes e nos controles, o COLV proveniente da cultura de fibroblastos dérmicos foi quantificado por PCR RT em tempo real e caracterizado por eletroforese, imunoblotting e reconstrução tridimensional, por meio da microscopia confocal. Resultados: O depósito de COLV foi maior na derme de pacientes com doença precoce, quando comparados aos controles e aos pacientes com doença tardia. A atividade e a duração da ES estiveram associadas com o depósito de COLV. A expressão de RNA mensageiro das cadeias COLV1 COLV2 foi aumentada em relação aos controles e a reconstrução tridimensional confirmou a presença de fibras anômalas de COLV. Observou-se maior expressão de caspase-3, endotelina-1, CTGF, TGF e VEGF nas células endoteliais dos pacientes com ES, quando comparados aos controles. Houve correlação positiva entre o depósito de COLV e a expressão de caspase-3, endotelina-1 e CTGF. Ao comparar-se os coelhos COLV-IM com os controles, observou-se aumento significativo da expressão de COLV aos 7 dias e de endotelina-1 aos 210 dias após a imunização. Embora de maneira não significativa, verificou-se maior expressão de caspase-3, CTGF e VEGF nos animais COLV-IM e, quando os animais foram comparados ao longo do tempo, percebeu-se maior expressão de COLV no sétimo dia após a imunização na derme dos animais COLV-IM, diminuindo no trigésimo dia e voltando a subir aos 75 dias e aos 210 dias. A caspase-3 e a endotelina-1 comportaram-se de maneira semelhante. Conclusão: Estes resultados sugerem que o COLV possa agir como um possível gatilho envolvido na patogênese da ES, agindo como um indutor de ativação e de apoptose endotelial, que por sua vez poderia resultar em maior expressão de COLV, perpetuando o processo de remodelamento observado na pele dos pacientes com ES / Introduction: The immunization of healthy rabbits with type V collagen (COLV) reproduces the main characteristics of systemic sclerosis (SSc), such as fibrosis, vasculopathy and specific auto-antibodies. Preliminary studies demonstrated that both COLV-immunized rabbits (COLV-IM) and SSc patients exhibit increased expression of abnormal COLV in the dermis, but the clinical relevance of this finding is unknown. The remodeling of the extracellular matrix is an early event in COLV-IM rabbits that can be detected by the seventh day after immunization; this observation suggests that COLV is involved in endothelial injury, one of the first manifestations of the disease. Thus, the objectives of this study were to evaluate COLV expression in the dermis of healthy controls and SSc patients and to determine the correlation of this expression with skin thickness, disease activity and duration and search for a possible association between this collagen with apoptosis and activation of endothelial cells markers in patients and in animal model induced by immunization with COLV. Patients and Methods: Skin biopsies from 18 patients (6 early-stage and 12 late-stage) and 10 healthy controls as well as skin biopsies from rabbits immunized with COLV (COLV-IM) and Freund adjuvant (N=6) or Freund adjuvant alone (N=6) were evaluated. Skin thickening assessment was performed with the Modified Rodnan Skin Score (MRSS), and activity was calculated using the Valentini Disease Activity Index. To perform quantification by histomorphometry, COLV was identified by immunofluorescence, and caspase-3, endothelin-1, CTGF, TGF and VEGF in dermal endothelial cells were labeled by immunohistochemistry. In SSc patients and healthy controls, COLV from dermal fibroblast culture was quantified by real-time RT-PCR and characterized by electrophoresis, immunoblotting and tridimensional reconstruction by confocal microscopy. Results: COLV deposition was increased in the dermis of the patients with early disease compared with the healthy controls and the patients with late disease. SSc activity and disease duration were associated with dermal COLV deposition. COLV1 and COLV2 mRNA expression levels were higher in SSc, and a tridimensional reconstruction of SSc dermal heterotypic fibers confirmed the presence of abnormal COLV. The dermal endothelial cell expression of caspase-3, endothelin-1, CTGF, TGF and VEGF was higher in the SSc patients than in the controls. There was a positive correlation between COLV deposition and caspase-3, endothelin-1 and CTGF expression. When the COLV-IM rabbits were compared with the controls, there was a significant increase in the expression of COLV 7 days after the immunization and a significant increase in the expression of endothelin-1 210 days after the immunization. The expression of caspase-3, CTGF and VEGF was higher in the COLV-IM animals than in the control rabbits, although not significantly, and when the rabbits were compared over time, the expression of COLV was higher in the dermis of the COLV-IM animals 7 days after immunization, decreasing at 30 days and increasing again at 75 and 210 days. Caspase-3 and endothelin-1 exhibited similar behavior. Conclusion: these results suggest that COLV can be a possible trigger involved in the pathogenesis of SSc, acting as an inducer of endothelial apoptosis and activation that could result in higher expression of COLV, perpetuating the remodeling process observed in SSc skin

O transplante autólogo de células-tronco hematopoéticas (TACTH) tem se mostrado mais eficaz como tratamento das formas graves da esclerose sistêmica (ES) do que a imunossupressão convencional (IS), porém os mecanismos imunológicos envolvidos com a resposta terapêutica não estão completamente elucidados. Células mononucleares do sangue periférico e soro/plasma foram coletados de 31 pacientes com ES antes e semestralmente, até 36 meses pós-transplante, e de 16 pacientes com ES não-transplantados tratados com IS. A função tímica foi avaliada por RT-qPCR dos valores de b- e signal joint (sj)-T-cell receptor excision circles (TREC), sendo a taxa de proliferação intratímica (n) calculada pela fórmula: n=LOG(sjTREC/bTREC)/LOG2. A história replicativa das células B e a função medular foram quantificadas pelos valores de coding-joint (Cj) e sj-kappa-deleting recombination excision circles (sjKREC) e a taxa de proliferação das células B no sangue periférico (N) foi calculada pela fórmula: N=LOG(Cj/sjKREC)/LOG2. O comprimento telomérico foi avaliado por RT-qPCR e estimado pela razão T/S (Telomere repeat copy number/Single-copy gene copy number). As células recém-emigradas do timo (RET) CD3+CD4+CD31+CD45RA+, T reguladoras (Tregs) CD4+CD25hiFoxP3+(GITR+/CTLA-4+), naïve CD19+CD27-IgD+, Bm2 CD19+CD38lowIgD+, B reguladoras (Bregs) CD19+CD24hiCD38hi, senescentes CD8+CD28- CD57+ e exaustas PD1+ foram quantificadas por citometria de fluxo. O TCR foi sequenciado por sequenciamento de nova geração e o perfil de citocinas séricas inflamatórias e pró- fibróticas foi avaliado por CBA-Flex e ELISA. Observamos que os valores de sjTREC e bTREC diminuíram aos 6 meses pós-TACTH, retornando a valores basais aos 12 meses, correlacionando com o número de RET e promovendo maior diversidade do TCR. Não houve mudança na taxa de divisão de timócitos. A contagem de Tregs aumentou aos 12 meses pósTACTH, correlacionando com valores de sjTREC e apresentando maior expressão de GITR e CTLA-4. A partir dos 12 meses, até o final do acompanhamento, os valores de sjKREC aumentaram, enquanto que os de Cj permaneceram estáveis, correlacionando com aumento da contagem de células B naïve e Bm2, e resultando em uma menor taxa de divisão de células B. Houve aumento de Bregs de 6 meses a um ano após o TACTH, cujos níveis correlacionaramse com aqueles de sjKREC, e apresentando maior produção de IL-10 mediante estímulo com CPG±CD40L do que antes do transplante. O comprimento telomérico diminuiu aos 6 meses pós-TACTH e correlacionou-se com níveis elevados de células senescentes que expressavam FoxP3, aliado a um aumento de expressão de PD1 pelas células T e redução dos níveis séricos de IL-6, IL-1b e proteína C reativa. Seis pacientes recaíram após o transplante, apresentando menor expressão de FoxP3, GITR e CTLA-4 pelas Tregs, diminuição da contagem de Breg e da diversidade do TCR. Adicionalmente, a remissão clínica foi associada a maior expressão de PD1 por células T e B e baixos níveis séricos de TGF-b, IL-6, IL-1b, IL-17A, MIP-1a, GCSF e IL-12. Portanto, o aumento de células T e B reguladoras geradas de novo pós-TACTH, associado à renovação do repertório de células T, alta expressão de PD1 e baixos níveis séricos de mediadores inflamatórios e prófibróticos, estão relacionadas com a resposta clínica dos pacientes com ES ao transplante. / Autologous hematopoietic stem cell transplantation (AHSCT) is more effective for patients with severe systemic sclerosis (SSc) than conventional immunosuppression (IS). However, the immunological mechanisms associated with the therapeutic efficacy of AHSCT are not fully elucidated. Peripheral blood mononuclear cells and serum/plasma were collected from 31 SSc patients before and semiannually, until 36 months post-transplant, and from 16 nontransplanted SSc patients treated with IS. Thymic function was measured by RT-qPCR quantification of ?- and signal joint (sj)-T-cell receptor excision circles (sjTREC) and intrathymic T-cell division (n) was calculated by the formula: n=LOG(sjTREC/?TREC)/LOG2. Bcell replication history and bone marrow function were assessed by coding-joint (Cj) and sjkappa-deleting recombination excision circles (sjKREC). B-cell divisions in the peripheral blood (N) were calculated by the formula: N=LOG(Cj/sjKREC)/LOG2. CD3+CD4+CD31+CD45RA+ recent thymic emigrants (RTE), CD4+CD25hiFoxP3+ (GITR+/CTLA-4+) regulatory T-cells (Tregs), CD19+CD27-IgD+ naïve B-cells, CD19+CD38lowIgD+ Bm2 B-cells, CD19+CD24hiCD38hi regulatory B-cells (Bregs), CD8+CD28-CD57+ senescent cells and PD1+ exhausted cells were quantified by FACS (fluorescence-activated cell sorting). The T-cell receptor (TCR) was sequenced by New Generation Sequencing and the profile of inflammatory and pro-fibrotic serum cytokines was evaluated by CBA-Flex (cytometric bead-array) and ELISA (enzyme-linked immunosorbent assay). sjTREC and ?TREC values decreased at 6 months post-AHSCT, returning to pretransplant values at 12 months, correlating with RTE counts and associated with higher diversity of the TCR. There was no change in thymocyte division rates. At 12 months postAHSCT, Treg counts increased and correlated with sjTREC values, presenting increased expression of GITR and CTLA-4 when compared to pre-transplant levels. From 12 months until the end of follow-up, sjKREC values increased, while those of Cj remained stable, correlating with increased counts of naïve and Bm2 B-cells, resulting in reduced rate of B-cell division. There was an increase of Breg frequency from 6-months until one-year after AHSCT, correlating with sjKREC values and presenting higher IL-10 production after stimulation with CPG±CD40L than before transplantation. Telomere length decreased at 6 months post-transplant and correlated with elevated levels of FoxP3-expressing senescent cells, together with increased expression of PD1 by T-cells and reduced serum IL-6, IL-1b and C-reactive protein levels. Six patients relapsed after transplantation, presenting lower expression of FoxP3, GITR, CTLA-4 by Tregs, decreased Breg counts and reduced TCR diversity. In addition, clinical remission was associated with increased PD1 expression by T and B cells and low serum levels of TGF-?, IL-6, IL-1, IL-17A, MIP-1, G-CSF and IL-12. Therefore, newly-generated regulatory T and B cells after AHSCT, associated with T-cell repertoire renewal, high PD1 expression and low serum levels of inflammatory and profibrotic mediators associate with clinical outcomes of SSc patients after AHSCT.